Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries
Cedric Popa; Karel Holvoet; Tessa Van Montfort; Floris Groeneveld; Steven Simoens · 2018 · Frontiers in Pharmacology
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
Background: Profits in the biopharmaceutical industry have been scrutinized in social debate. However, drawing conclusions based on industry profitability only is inappropriate as such an analysis does not account for risks faced by investors. This study aims to measure risks and returns in the biopharmaceutical industry and investigates whether risk-adjusted return on investment in the biopharmaceutical industry is higher than that in other industries. Methods: To enable appropriate comparison, we identified six benchmark industries with characteristics that match those of the biopharmaceutic
Abstract by Cedric Popa; Karel Holvoet; Tessa Van Montfort; Floris Groeneveld; Steven Simoens, Frontiers in Pharmacology (2018) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
The Oregon Experiment — Effects of Medicaid on Clinical Outcomes
Negative / Null Result ReportMicrocredit in Theory and Practice: Using Randomized Credit Scoring for Impact Evaluation
Negative / Null Result ReportThe Cost of Carbon: Capital Market Effects of the Proposed Emission Trading Scheme (ETS)
Negative / Null Result ReportPushing on a string: US monetary policy is less powerful in recessions ∗
Negative / Null Result ReportThe Evidence on Globalisation
Negative / Null Result ReportStatistical tests for power-law cross-correlated processes
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.3389/fphar.2018.01108